VEGF News and Research RSS Feed - VEGF News and Research

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.
Angiotensin system inhibitor use improves metastatic RCC survival outcomes

Angiotensin system inhibitor use improves metastatic RCC survival outcomes

Use of angiotensin system inhibitors is associated with significant survival benefits in metastatic renal cell carcinoma patients treated in the targeted therapy era, research findings indicate. [More]
Discovery may lead to new potential treatment for drug-resistant melanoma

Discovery may lead to new potential treatment for drug-resistant melanoma

In the last several years, targeted therapies - drugs that directly impact specific genes and proteins involved in the progression of cancer - have been approved for a wide variety of cancers, including melanoma, the deadliest form of skin cancer. Now, researchers at The Wistar Institute have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, and understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments. [More]
Selten Pharma's SPI-026 granted FDA Orphan Drug Designation for treatment of PAH

Selten Pharma's SPI-026 granted FDA Orphan Drug Designation for treatment of PAH

Selten Pharma, Inc., a privatively held biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare diseases, announced today that its lead compound tacrolimus (SPI-026) has been granted Orphan Drug Designation by the U.S. Food & Drug Administration for the treatment of pulmonary arterial hypertension (PAH). [More]
Study: Cancer drug may help reduce bleeding in HHT patients

Study: Cancer drug may help reduce bleeding in HHT patients

A cancer drug that helps keep tumors from growing blood vessels may help patients with a rare genetic condition in which malformed vessels increase their risk for bleeding and anemia. [More]
Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron Pharmaceuticals, Inc. today announced that EYLEA (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Macular Edema secondary to Retinal Vein Occlusion (RVO). [More]
Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years). [More]
Study results report no benefit from use of sunitinib, sorafenib among patients with kidney cancer

Study results report no benefit from use of sunitinib, sorafenib among patients with kidney cancer

Research results highlighted today at the press conference of a major medical meeting report no benefit from the use of either Sutent (sunitinib) or Nexavar (sorafenib) among patients with locally advanced renal cell carcinoma at high risk of recurrence, the ECOG-ACRIN Cancer Research Group announced. [More]
Johns Hopkins researcher helps discover effectiveness of three drugs for treating patients with DME

Johns Hopkins researcher helps discover effectiveness of three drugs for treating patients with DME

A researcher from Johns Hopkins Medicine helped lead colleagues from across the country in a government-sponsored study by the Diabetic Retinopathy Clinical Research Network to discover that three drugs -- Eylea, Avastin and Lucentis -- used to treat diabetic macular edema are all effective. They also discovered that Eylea outperformed the other two drugs when vision loss was moderate to severe. [More]
Researchers reveal new understanding of pathobiology behind vestibular schwannoma

Researchers reveal new understanding of pathobiology behind vestibular schwannoma

Researchers from the Eaton-Peabody Laboratories of Massachusetts Eye and Ear and the Harvard Medical School/ Massachusetts Institute of Technology Program in Speech and Hearing Bioscience and Technology have revealed new understanding of the pathobiology behind a head and neck tumor that may someday lead to new methods of targeted drug therapy. [More]
Clinical study comparing effectiveness of three standard treatments for DME published in NEJM

Clinical study comparing effectiveness of three standard treatments for DME published in NEJM

Regeneron Pharmaceuticals, Inc. today announced that results from the National Institutes of Health-sponsored, Diabetic Retinopathy Clinical Research Network comparative effectiveness study in patients with Diabetic Macular Edema (Protocol T) were published in the New England Journal of Medicine and a corresponding slide set was posted online at DRCR.net. [More]
Eight clinical researchers selected as finalists for Outstanding Investigator Award at Cardiology 2015

Eight clinical researchers selected as finalists for Outstanding Investigator Award at Cardiology 2015

Pediatric cardiology researchers and clinicians from numerous centers from around the world are gathering at the Cardiology 2015: the 18th Annual Update on Pediatric and Congenital Cardiovascular Disease conference, sponsored by The Children's Hospital of Philadelphia and Phoenix Children's Hospital on Feb. 11 to Feb. 15 in Scottsdale, Ariz. [More]
Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). [More]
Omega-3 could supplement anti-VEGF treatment in AMD

Omega-3 could supplement anti-VEGF treatment in AMD

Pilot study findings suggest that taking omega-3 fatty acid supplements could increase the efficacy or reduce the needed frequency of anti-vascular endothelial growth factor treatment in patients with exudative age-related macular degeneration. [More]
Retinal venular calibre predicts ranibizumab vision improvement

Retinal venular calibre predicts ranibizumab vision improvement

Retinal venular calibre may predict visual outcome in diabetic macular oedema patients given the anti-vascular endothelial growth factor monoclonal antibody ranibizumab, a pilot study suggests. [More]
Meta-analysis gives intravitreal ranibizumab vascular adverse risk profile

Meta-analysis gives intravitreal ranibizumab vascular adverse risk profile

Intravitreal ranibizumab treatment for age-related macular degeneration does not elevate the risk of mortality, suggests a meta-analysis published in Ophthalmology. [More]

VEGF inhibition does not regulate collateral vessels in retinal vein occlusion

The formation of collateral vessels does not appear to improve visual acuity in patients with branch or central retinal vein occlusion, and is unaffected by anti-vascular endothelial growth factor therapy, a retrospective analysis suggests. [More]
Pfenex, Hospira sign agreement to develop and commercialize LUCENTIS biosimilar

Pfenex, Hospira sign agreement to develop and commercialize LUCENTIS biosimilar

Pfenex Inc., a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, and Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today announced that the companies have entered into an agreement to exclusively develop and commercialize for worldwide sales PF582, Pfenex's biosimilar candidate to Genentech's LUCENTIS (ranibizumab injection). [More]
NYEE ophthalmologists offer prevention tips to observe AMD Awareness Month

NYEE ophthalmologists offer prevention tips to observe AMD Awareness Month

Macular degeneration is a major cause of irreversible vision loss in the United States and around the world. As many as 11 million Americans have some form of macular degeneration. [More]
Study: Lower-income students in China have better vision compared to middle-class counterparts

Study: Lower-income students in China have better vision compared to middle-class counterparts

In one of the largest population-based studies ever conducted on nearsightedness in children, researchers have discovered that lower-income students in China have better vision than their middle-class counterparts. Data show that nearsightedness, also called myopia, is twice as prevalent in the middle-income province of Shaanxi compared to the poorer neighboring province of Gansu. [More]
Mathematical models of cancer behavior offer new insights on tumor growth

Mathematical models of cancer behavior offer new insights on tumor growth

Hassan Fathallah-Shaykh, M.D., Ph.D., believes that math can transform medicine, and he has the numbers to prove it. [More]
Advertisement
Advertisement